Are there contraindications to the use of Ashwagandha in patients with Rheumatoid Arthritis (RA) or other autoimmune diseases?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

Ashwagandha should be used with caution in patients with rheumatoid arthritis and other autoimmune diseases, as its immune-stimulating effects could potentially worsen autoimmune conditions. While some research suggests ashwagandha has anti-inflammatory properties that might theoretically help with symptoms, its impact on an already overactive immune system in autoimmune diseases is a concern 1, 2. The American College of Rheumatology guidelines for rheumatoid arthritis management do not specifically address the use of ashwagandha, but they do emphasize the importance of an integrative management approach that includes exercise, rehabilitation, diet, and additional interventions in conjunction with disease-modifying antirheumatic drugs (DMARDs) 1, 2.

Key considerations for the use of ashwagandha in patients with autoimmune diseases include:

  • Potential interactions with immunosuppressive medications, which could reduce their effectiveness
  • The need for careful monitoring of disease activity and symptoms
  • Individualization of the decision to use ashwagandha based on the patient's specific condition, medication regimen, and disease activity
  • Starting with a low dose (perhaps 300mg daily) under medical supervision to minimize potential risks

It is essential for patients with autoimmune conditions to discuss the use of ashwagandha with their rheumatologist or primary care provider before starting, given the potential for both beneficial and harmful effects depending on the individual's immune response 3. The European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis also highlight the importance of a personalized approach to treatment, considering factors such as disease activity, prognostic factors, and patient preferences 3.

In the absence of specific guidelines on the use of ashwagandha in autoimmune diseases, healthcare providers must rely on their clinical judgment and the available evidence to make informed decisions about its use. Given the potential risks and benefits, a cautious approach is warranted, with careful consideration of the individual patient's circumstances and close monitoring for any adverse effects.

From the Research

Contraindications of Ashwagandha in Autoimmune Diseases

  • There is limited research directly addressing the contraindications of Ashwagandha in patients with Rheumatoid Arthritis (RA) or other autoimmune diseases.
  • However, a study published in 2015 4 found that Withania somnifera (Ashwagandha) root extract had anti-arthritic activity in collagen-induced arthritic rats, suggesting potential benefits in reducing oxidative stress and autoantibodies production.
  • The same study 4 also found that Ashwagandha root extract reduced inflammation in CIA rats, which could be beneficial for patients with RA.
  • On the other hand, there is no direct evidence from the provided studies 5, 6, 7, 8 to suggest that Ashwagandha is contraindicated in patients with RA or other autoimmune diseases.
  • In fact, the studies 5, 6, 7, 8 focus on the treatment options and management of RA, highlighting the importance of disease-modifying antirheumatic drugs (DMARDs) and early diagnosis, but do not mention Ashwagandha or its potential interactions with these treatments.

Potential Interactions and Considerations

  • While Ashwagandha may have potential benefits in reducing oxidative stress and inflammation, its interaction with conventional RA treatments, such as DMARDs, is not well understood.
  • Patients with RA or other autoimmune diseases should consult their healthcare provider before using Ashwagandha or any other complementary therapy, as it may interact with their medications or exacerbate their condition.
  • Further research is needed to fully understand the effects of Ashwagandha on autoimmune diseases and its potential interactions with conventional treatments.

Related Questions

In a 68-year-old woman with rheumatoid arthritis on methotrexate and Simponi (golimumab) who now has macrocytosis (MCV 97.2 fL), thrombocytopenia (platelet count 74 ×10⁹/L), and elevated mean platelet volume (MPV 12.7 fL), what is the most likely cause and how should it be managed?
What pain management options are appropriate for a 70‑year‑old woman with longstanding rheumatoid arthritis and wrist pain, who is on amlodipine 10 mg daily, low‑dose aspirin after a prior stroke, and has not used glucocorticoids since a brief prednisone course?
What is the appropriate treatment for an 87‑year‑old female with rheumatoid arthritis and limited ambulation who has erythema and tenderness of the great toe?
What is the most appropriate initial management for a 40-year-old woman with rheumatoid arthritis (positive rheumatoid factor) presenting with three months of morning hand and wrist stiffness, swelling, and warmth of the wrists, metacarpophalangeal joints, and proximal interphalangeal joints?
What is the likely diagnosis and recommended evaluation and management for a 26‑year‑old woman presenting with three weeks of wrist, MCP, and PIP joint pain, morning stiffness lasting 45–60 minutes, mild swelling, facial erythematous rash, low‑grade fever, foamy urine, and bilateral lower‑extremity edema?
Should IUD removal or Pap smear be performed first?
What is the risk, prognosis, and management of cerebral cavernous malformations (cavernoma)?
Is vaginal estrogen cream a possible treatment for vaginal lichen sclerosis in a postmenopausal (post-menopausal) female with impaired vaginal health?
What is the diagnosis for a patient with multilevel chronic degenerative spondylosis, disc space narrowing, attenuated disc hydration signal, diffuse disc bulge, and varying degrees of spinal canal stenosis and neural foraminal encroachment at levels L1-L2, L2-L3, L3-L4, L4-L5, and L5-S1, with stable Grade 2 anterolisthesis of L4 on L5?
Can hyperkalemia (elevated potassium levels) cause right axis deviation?
Will a combination of vaginal estrogen cream and clobetasol (clobetasol propionate) help a 77-year-old female with vaginal atrophy and lichen sclerosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.